Overexpression of serine hydroxymethyltransferase SHMT2 is also associated with poor prognosis in cancer patients, while downregulating this enzyme suppresses tumorigenesis in human hepatocellular carcinoma (86). Here, SHMT2 is linked to hepatocellular carcinoma.